Cardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) has received an average recommendation of "Buy" from the five brokerages that are currently covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $8.67.
Separately, HC Wainwright began coverage on shares of Cardiol Therapeutics in a research report on Monday, June 2nd. They issued a "buy" rating and a $9.00 price objective on the stock.
Get Our Latest Stock Report on Cardiol Therapeutics
Institutional Investors Weigh In On Cardiol Therapeutics
A number of large investors have recently added to or reduced their stakes in the company. Tejara Capital Ltd boosted its stake in shares of Cardiol Therapeutics by 75.9% in the 4th quarter. Tejara Capital Ltd now owns 3,115,437 shares of the company's stock valued at $3,988,000 after purchasing an additional 1,344,167 shares in the last quarter. PVG Asset Management Corp bought a new position in shares of Cardiol Therapeutics during the fourth quarter valued at about $624,000. Envestnet Asset Management Inc. purchased a new position in shares of Cardiol Therapeutics in the fourth quarter worth about $398,000. Atria Investments Inc bought a new stake in shares of Cardiol Therapeutics in the 4th quarter valued at about $174,000. Finally, Virtu Financial LLC purchased a new stake in Cardiol Therapeutics during the 4th quarter valued at about $61,000. Hedge funds and other institutional investors own 12.49% of the company's stock.
Cardiol Therapeutics Price Performance
NASDAQ:CRDL traded up $0.06 during trading hours on Friday, hitting $1.34. The stock had a trading volume of 126,875 shares, compared to its average volume of 316,245. The company has a 50 day simple moving average of $1.19 and a two-hundred day simple moving average of $1.20. The firm has a market capitalization of $110.75 million, a price-to-earnings ratio of -3.94 and a beta of 1.03. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.26 and a quick ratio of 3.26. Cardiol Therapeutics has a one year low of $0.77 and a one year high of $2.63.
Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report) last posted its quarterly earnings data on Monday, March 31st. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01. Research analysts forecast that Cardiol Therapeutics will post -0.33 earnings per share for the current fiscal year.
About Cardiol Therapeutics
(
Get Free ReportCardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Featured Articles
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
